Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABEO
HoldHot AirAbeona Therapeutics Inc. · Healthcare · United States · $339M · Avg Vol: $8M/d
COMPANY DESCRIPTION
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for life-threatening rare genetic diseases. The company's competitive advantage is anchored by its proprietary retroviral vector platforms and state-of-the-art, in-house GMP manufacturing facility. Its lead clinical program targets recessive dystrophic epidermolysis bullosa (RDEB), positioning it as a specialized player in the high-value gene therapy sector.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4M | 3.5M | 0 | 5.8M | 60.3% | 25.5M | 54.3M | 118.9M | 351.9% |
| EPS | -1.72 | -1.18 | -1.55 | 1.34 | — | -1.21 | 1.73 | — | 29.3% |
| Shares | 57.0M | 57.0M | 45.6M | 55.0M | -3.4% | 57.2M | — | — | — |
| Debt | 7.6M | 5.4M | 23.0M | 25.0M | 48.5% | 19.9M | — | — | — |
| Equity | 26.8M | 14.8M | 44.0M | 159.2M | 81.2% | — | — | — | — |
| Op CF | -43.5M | -37.0M | -56.0M | -76.3M | — | -76.4M | — | — | — |
| Inv CF | -24.0M | 0.2M | -39.2M | 105.0M | — | — | — | — | — |
| Fin CF | 43.2M | 37.1M | 104.1M | 26.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABEO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABEO | Abeona Therapeutics Inc.(you) | $339M | 39 | Hold |
| NAGE | Niagen Bioscience, Inc. | $260M | 38 | Hold |
| IKT | Inhibikase Therapeutics, Inc. | $336M | 32 | Sell |
| PALI | Palisade Bio, Inc. | $349M | 33 | Sell |
| WHWK | Whitehawk Therapeutics, Inc. | $263M | 35 | Hold |
| ARTV | Artiva Biotherapeutics, Inc. | $542M | 37 | Hold |
| ARVN | Arvinas, Inc. | $592M | 40 | Hold |
| OVID | Ovid Therapeutics Inc. | $547M | 35 | Sell |
| OABI | OmniAb, Inc. | $650M | 40 | Hold |
| SABS | SAB Biotherapeutics, Inc. | $345M | 25 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%